Zepbound (tirzepatide) and Wegovy (semaglutide) are the two FDA-approved injectable medications for chronic weight management. The honest answer to “which is better?” is Zepbound, on effectiveness alone — but the full picture is more nuanced.
What the head-to-head trial showed
SURMOUNT-5 directly compared tirzepatide to semaglutide for weight loss over 72 weeks in adults with obesity (without diabetes):
| Outcome | Zepbound (tirzepatide) | Wegovy (semaglutide) |
|---|---|---|
| Mean weight loss | 20.2% | 13.7% |
| ≥15% weight loss | 65% of patients | 40% |
| ≥25% weight loss | 32% | 16% |
Tirzepatide won on every effectiveness endpoint. That’s the strongest head-to-head evidence we have.
Where Wegovy still has an edge
- Cardiovascular outcomes data. The SELECT trial established that semaglutide reduces major adverse cardiovascular events by 20% in adults with obesity and existing CVD. Tirzepatide’s CV outcomes trial (SURPASS-CVOT) reports out later in 2026.
- Longer real-world track record. Semaglutide has been on the market since 2017 (as Ozempic); tirzepatide since 2022.
- Pediatric approval. Wegovy is approved for adolescents 12+. Zepbound is not.
- Sleep apnea indication. Zepbound has this; Wegovy does not (yet).
Cost & access
| Zepbound | Wegovy | |
|---|---|---|
| List price | ~$1,086/mo | ~$1,349/mo |
| Self-pay program | Lilly Direct vials ~$349–$549 | NovoCare savings card |
| Supply | Generally stable in 2026 | Recovering from earlier shortages |
Lilly Direct’s vial pricing makes Zepbound meaningfully cheaper for cash-pay patients.
So which should you take?
- Default choice for most adults with obesity: Zepbound. More weight loss, lower self-pay price, dual-mechanism advantage.
- Existing cardiovascular disease: Wegovy has the proven outcomes data.
- Adolescent: Wegovy (only one approved for ages 12+).
- History of severe GI sensitivity: Some patients tolerate semaglutide better, though tirzepatide’s nausea profile is roughly comparable in trials.
Insurance coverage frequently makes the decision regardless of preference. Check your formulary before getting attached to either.
See also
- Zepbound full review
- Wegovy full review
- Mounjaro vs Ozempic — the diabetes counterparts.
- Full comparison table of every GLP-1 medication.
- How GLP-1s work — why a dual GLP-1/GIP agonist outperforms a pure GLP-1.
- How to get a prescription
Educational content only — not medical advice. Always consult a licensed clinician before starting or changing GLP-1 therapy.